Healthcare >> CEO Interviews >> October 5, 2018
Hugh Griffith is the Founder and Chief Executive Officer as well as a member of the board of directors of NuCana plc since it commenced operations in 2008. In addition, he currently serves as a nonexecutive director of EdixoMed Limited and MedAnnex Limited, biotech companies that he co-founded in 2009. He also serves as director of Alida Capital International, a biotech business angel syndicate that he formed in 2009. Prior to founding NuCana, Mr. Griffith was Chief Operating Officer of Bioenvision, Inc., a biopharmaceutical company, from 2002 until 2007, when it was acquired by Genzyme Corporation — now Sanofi. Before that, Mr. Griffith held several senior commercial positions at Quantanova Limited, a biopharmaceutical company; Abbott Laboratories, now AbbVie Inc.; and Warner-Lambert Company, now Pfizer Inc. He currently serves on the advisory board of the Scottish Lifesciences Association. Mr. Griffith received an MBA from Cardiff Business School and a B.S. honors in biology from the University of Stirling. Profile
Word count: 3,059
TWST: What is NuCana's core technology?
Mr. Griffith: NuCana is exploiting an extremely innovative medicinal chemistry approach known as